+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 100Years
MALE
ID06855277

Phase III Study Comparing 225Ac-PSMA-617 Plus Androgen Receptor Pathway Inhibitors Versus Standard Treatments in Adult Men with PSMA-positive Metastatic Castration Resistant Prostate Cancer

Led by Novartis Pharmaceuticals · Updated on 2026-10-15

940

Participants Needed

106

Research Sites

213 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether 225Ac-PSMA-617 AAA817 combined with androgen receptor pathway inhibitors ARPI prolongs radiographic progression-free survival rPFS compared to standard treatments in adult men with PSMA-positive metastatic castration-resistant prostate cancer mCRPC. The study focuses on participants who have previously been treated with ARPI but not taxane chemotherapy or prior PSMA-targeting radioligand therapy in the mCRPC setting. This phase III, open-label, randomized study is conducted globally including the USA. Participants are randomly assigned to receive either up to six intravenous doses of AAA817 at 10 Megabecquerel MBq plus oral ARPI enzalutamide or abiraterone, or one of the standard care options chosen by investigators. Standard care options include switching ARPI, taxane-based chemotherapy docetaxel or cabazitaxel, or 177Lu-PSMA-617 AAA617 radioligand therapy. Treatment with ARPI continues per protocol until defined end of treatment criteria. Supportive care including androgen deprivation therapy is allowed in both groups. Crossover between groups is not permitted. Participants undergo screening to confirm eligibility including PSMA-positive status via PETCT scans. Throughout the study, safety assessments are performed regularly. Researchers will measure outcomes including radiographic progression-free survival up to approximately 40 months after randomization, as well as overall survival and other cancer progression markers. The study also monitors treatment responses, pain levels, and quality of life measures. Participants remain under observation for the duration of the study until the end date in 2032.

CONDITIONS

Brief Title

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

Research Team

N

Novartis Pharmaceuticals

N

Novartis Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here